Shares of iBio Inc. IBIO inched 0.41% higher to $2.46 Monday, on what proved to be an all-around mixed trading session for ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

iBio Inc. closed $2.56 short of its 52-week high ($4.98), which the company reached on March 28th.

An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

Bio (IBIO) announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially ...

Under this License Agreement, iBio will have exclusive rights, including sublicensing capabilities, for the development and commercialization of the product worldwide. In consideration for these ...

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today ...

Shares of iBio, Inc. (NYSE:IBIO – Get Free Report) rose 2.5% during trading on Wednesday . The company traded as high as $2.44 and last traded at $2.42. Approximately 57,343 shares changed hands ...

iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...

(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio ...